Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.70 |
| ▸ | RET | P07949 | 8/20 | 0.70 |
| ▸ | KIF5B | P33176 | 5/20 | 0.70 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 10/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.53 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.53 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7454703 | 0.99 | KDR (0.69) | KDRRETKIF5BBRAFEGFR | |
| SCHEMBL8305217 | 0.89 | EGFR (0.58) | KDRRETKIF5BEGFRRIPK2 | |
| SCHEMBL8306865 | 0.85 | EGFR (0.58) | KDRRETKIF5BEGFRRIPK2 | |
| SCHEMBL5651286 | 0.84 | KDR (1.00) | KDRRETKIF5BBRAFEGFR | |
| Hydrochloric Acid SCHEMBL7859467 | 0.83 | KDR (0.98) | KDRRETKIF5BBRAFEGFR | |
| SCHEMBL7451139 | 0.77 | KDR (0.70) | KDRRETKIF5BBRAFEGFR | |
| Hydrochloric Acid SCHEMBL7712344 | 0.77 | KDR (0.69) | KDRRETKIF5BBRAFEGFR | |
| SCHEMBL5652377 | 0.77 | KDR (0.83) | KDRRETKIF5BBRAFEGFR | |
| SCHEMBL7454466 | 0.76 | KDR (0.78) | KDRRETKIF5BBRAFEGFR | |
| Hydrochloric Acid SCHEMBL7865973 | 0.76 | KDR (0.82) | KDRRETKIF5BBRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | claimed |
| EP-0873319-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-07-25 | — | — | EP | claimed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | claimed |
| US-6362336-B1 | ADMINISTERING A QUINAZOLINE DERIVATIVE TO A WARM-BLOODED ANIMAL FOR PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2002-03-26 | — | — | US | disclosed |
| US-20020032208-A1 | Chemical compounds | ZENECA LIMITED | 2002-03-14 | — | — | US | disclosed |
| US-6258951-B1 | ANTICANCER, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 2001-07-10 | — | — | US | disclosed |
| US-6071921-A | Chemical compounds | ZENECA LIMITED (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5962458-A | ANGIOGENESIS INHIBITORS, ANTICANCER AGENTS, ANTIDIABETIC AGENTS, SKIN DISORDERS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, VISION DEFECTS | ZENECA LIMITED (GB) | 1999-10-05 | — | — | US | disclosed |
| EP-0873319-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-10-28 | — | — | EP | disclosed |
| WO-1997022596-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032208-A1 | Chemical compounds | FLT1, CNKSR1, KDR | KDR 3/4885RET 466/4885KIF5B 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.